Inactive

Sources Sought notice is a market research tool being used to determine availability and adequacy of potential business sources. The Medical Readiness Contracting Office-West is issuing this Sources S... Sources Sought notice is a market research tool being used to determine availability and adequacy of potential business sources. The Medical Readiness Contracting Office-West is issuing this Sources Sought Notice on behalf of Brooke Army Medical Center (BAMC) JBSA - Fort Sam Houston, Texas. Any responses to this Sources Sought Notice will be used for planning purposes only. Based on the responses to this notice, the requirement may be set-aside for small businesses, procured through full-and-open competition, or result in a sole-source contract. The proposed North American Industry Classification System (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing, with a corresponding size standard of 1,300 employees. BAMC has a requirement for LUTATHERA and PLUVICTO doses. This requirement is for two FDA Approved products. Lutathera, is indicated for the imaging and treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Pluvicto is for the treatment of adult patients with prostrate specific membrane antigen-positive metastatic castration-resistant prostate cancer. The contemplated contract type is an Indefinite-Delivery Indefinite-Quantity contract with firm-fixed-price line items. Medications will be delivered from 01 October 2024 - 30 September 2029. (Five (5) Ordering Periods) Salient Characteristics: Lutetium Lu-177 Dotatate (Lutathera) Must be FDA approved. Must be Lu-177 Dotatate. Must be indicated for treatment of somatostatin receptor-positive gastroenterpancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors. Should be a 4 dose treatment regimen given every 8 weeks. Lutetium Lu-177 Vipivotide Tetraxetan (Pluvicto) Must be FDA approved. Must be Lu-177 Vipivotide Tetraxetan. Must be indicated for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Should be a treatment regimen of every 6 weeks for up to 6 doses. If your organization has the potential capacity to provide Lutathera and Pluvicto, please provide the following information: 1) Organization name, address, Point of Contact name and e-mail address, Web site address, telephone number, Commercial and Government Entity (CAGE) Code and size (small versus large business, and any other socio-economic categories) and type of ownership for the organization; 2) Tailored capability statements addressing the particulars of this effort, with appropriate documentation supporting claims of organizational capability, to include proof of authorization to provide supplies. THERE IS NO SOLICITATION AT THIS TIME. This request for capability information does not constitute a request for proposals; submission of any information in response to this notice is purely voluntary; the Government assumes no financial responsibility for any costs incurred. Contractors responding to this sources sought notice are advised their response does not ensure participation in future solicitations or contract awards. The Government WILL NOT provide a debrief on the results of the sources sought and will not reimburse for any cost associated with preparing a response. All information submitted will be held in a confidential manner and will only be used for the purpose intended. Interested parties should e-mail responses to Ms. Rosalba Martinez @ Rosalba.martinez1.civ@health.mil and Ms. Andrea Vigliotti @ Andrea.j.vigliotti.civ@health.mil by the date identified below. Submit response no later than 8 May 2024 at 3:00pm CST.